A randomized open-label comparison of lamotrigine and valproate in patients with juvenile myoclonic epilepsy

International Journal of Pharmacology

Volumn 5, Issue 5, 2009, Pages 313-318

  Nejad, S E M ^a   Nikpour, Mohammad Reza Amiri ^a   Rahim, F ^b   Naghibi, S N ^a   Bahrammi, M A ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Juvenile myoclonic epilepsy; Lamotrigine; Valproate

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; HAIR LOSS; HUMAN; JUVENILE MYOCLONIC EPILEPSY; MAINTENANCE THERAPY; MENSTRUAL IRREGULARITY; MYALGIA; MYOCLONUS EPILEPSY; NAUSEA; NERVOUSNESS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL CHILD; SIDE EFFECT; SLEEP PATTERN; SOMNOLENCE; THERAPY EFFECT; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREMOR; UNIVERSITY HOSPITAL; WAKEFULNESS; WEIGHT GAIN;

EID: 70449652637     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2009.313.318     Document Type: Article

References (44)

1. Alfradique, I. and M.M. Vasconcelos, 2007. Juvenile myoclonic epilepsy. Arq. Neuropsiquiatr., 65: 1266-1271.
2. Atakli, D., D. Sozuer, T. Atay, S. Baybas and B. Arpaci, 1998. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure, 7: 63-66. (Pubitemid 28121952)
3. Auvin, S., 2008. Treatment of juvenile myoclonic epilepsy. CNS Neurosci. Ther., 14: 227-233.
4. Banerjee, P.N., D. Filippi and W.A. Hauser, 2009. The descriptive epidemiology of epilepsy-a review. Epilepsy Res., 85: 31-45.
5. Cetinkaya, F., E. Sennaroglu and S. Comu, 2008. Etiologies of seizures in young children admitted to an inner city hospital in a developing country. Pediatr. Emerg. Care, 24: 761-763.
6. Choi, H. and M.J. Morrell, 2003. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacother., 4: 243-251.
7. Coppola, G., F. Licciardi, N. Sciscio, F. Russo, M. Carotenuto and A. Pascotto 2004. Lamotrigine as first-line drug in childhood absence epilepsy: A clinical and neurophysiological study. Brain Dev., 26: 26-29. (Pubitemid 38083182)
8. Cramer, J.A., D.B. Smith, R.H. Mattson, A.V.D. Escueta and J.F. Collins, 1983. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology, 33: 26-37. (Pubitemid 13147839)
9. Cramer, J.A., E. Ben-Menachem and J. French, 2001. Review of treatment options for refractory epilepsy: New medications and vagal nerve stimulation. Epilepsy Res., 47: 17-25.
10. Culy, C.R. and K.L. Goa, 2000. Lamotrigine. A review of its use in childhood epilepsy. Paediatr. Drugs, 2: 299-330.
11. Engel, J. Jr., 2006. ILAE classification of epilepsy syndromes. Epilepsy Res., 70: 5-10.
12. Faught, E., F.U. Matsuo, S. Schachter, J. Messenheimer and G.P. Womble, 2004. Long-term tolerability of lamotrigine: Data from a 6-year continuation study. Epilepsy Behav., 5: 31-36. (Pubitemid 38937061)
13. French, J.A., A.S.M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne and C.L. Harden et al., 2004. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: Report of the TTA and QSS subcommittees of the American academy of neurology and the American epilepsy society. Epilepsia, 45: 401-409.
14. Gamble, C.L., P.R. Williamson and A.G. Marson, 2006. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst. Rev., 25: CD001031-CD001031.
15. Herzog, A., F.W. Drislane and D.I. Schomer, 2003. Differential antiepileptic drug effects on sex hormones and reproductive hormones: A comparison between lamotrigne and enzyme-inducing antiepileptic drugs. Epilepsia, 44: 107-115.
16. Holmes, G.L., L.M. Frank, R.D. Sheth, B. Philbrook and J.D. Wooten et al., 2008. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res., 82: 124-132.
17. Jallon, P. and P. Latour, 2005. Epidemiology of idiopathic generalized epilepsies. Epilepsia, 46: S10-S14.
18. Karceski, S., M.J. Morrell and D. Carpenter, 2005. Treatment of epilepsy in adults: Expert opinion, Epilepsy Behav., 7: S1-S64. (Pubitemid 41131320)
19. Karlovassitou-Koriari, A., D. Alexiou and P. Angelopoulos et al., 2002. Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy. J. Neurol., 249: 396-399.
20. Kilaru, S. and A.G. Bergqvist, 2007. Current treatment of myoclonic astatic epilepsy: Clinical experience at the children's hospital of Philadelphia. Epilepsia, 48: 1703-1707. (Pubitemid 47352882)
21. Kleveland, G. and B. Engelsen, 1998. Juvenile myoclonic epilepsy: Clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure, 7: 31-38. (Pubitemid 28121947)
22. Koristkova, B., U. Bergman, M. Grundmann, H. Brozmanova and F. Sjoqvist, 2006. Therapeutic monitoring of antiepileptic drugs: A comparison between a Czech and a Swedish university hospital. Ther. Drug Monit., 28: 594-598.
23. Maiga, Y., B. Nogues and B. Guillon, 2006. Exacerbation of tonicoclonic seizures in a juvenile myoclonic epileptic taking lamotrigine. Rev. Neurol., 162: 1125-1127.
24. Mehndiratta, M.M. and P. Aggarwal, 2002. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (Juvenile myoclonic epilepsy) from North India. Seizure, 11: 431-436.
25. Mohanraj, R. and M. Brodie, 2005. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav., 6: 382-387. (Pubitemid 40468428)
26. Neels, H.M., A.C. Sierens, K. Naelaerts, S.L. Scharpe, G.M. Hatfreld and W.E. Lambert, 2004. Therapeutrc drug monitoring of old and newer anti-epileptic drugs. Clin. Chem. Lab. Med., 42: 1228-1255.
27. Nicolson, A., R. Appelton, D. Chadwick and D.F. Smith, 2004. The relationship between treatment with valproate, lamotrigine and topiramate and the prognosis of idiopathic generalised epilepsies. J. Neurol. Neurosurg. Psychiatry, 75: 75-79.
28. Pack, A.M., L.S. Olarte and M.J. Morell, 2003. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav., 4: 169-174.
29. Panagariya, A., R. Sureka and V. Ardana, 2001. Juvenile myoclonic epilepsy-an experience from North Western India. Acta Neurol. Scand, 104: 12-16.
30. Panayiotopoulos, C.P., 2000. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology, 54: 777-777
31. Perucca, E., 2002. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs, 16: 695-714. (Pubitemid 35176854)
32. Peterson, G.M. and M. Naunton, 2005. Valproate: A simple chemical with so much to offer. J. Clin. Pharm. Ther., 30: 417-421.
33. Pina-Garza, J.E., P. Levisohn, K. Gucuyener, M.A. Mikati, C.R. Warnock, H.S. Conklin and J. Messenheimer, 2008. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology, 70: 2099-2108.
34. Posner, E.B., K. Mohamed and A.G. Marson, 2005. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst. Rev., 19: CD003032-CD003032.
35. Prasad, A., R.I. Kuzniecky, R.C. Knowlton, T.E. Welty, R.C. Martin and M. Mendez et al., 2003. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol., 60: 1100-1105.
36. Saetre, E., E. Perucca, J. Isojarvi and L. Gjerstad, 2007. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia, 48: 1292-1302. (Pubitemid 47063092)
37. Stefan, H. and T.J. Feuerstein, 2007. Novel anticonvulsant drugs. Pharmacol. Ther., 113: 165-183.
38. Steinhoff, B.J., M.A. Ueberall, H. Siemes, G. Kurlemann, B. Schmitz and L. Bergmann, 2005. The LAM-SAFE study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure, 14: 597-605.
39. Stephen, L.J., 2003. Drug treatment of epilepsy in elderly people: Focus on valproic acid. Drugs Aging, 20: 141-152.
40. Trevathan, E., S.P. Kerls, A.E. Hammer, A. Vuong and J.A. Messenheimer, 2006. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics, 118: 371-378. (Pubitemid 46090507)
41. Tuxhorn, I. and P. Kotagal, 2008. Classification. Semin. Neurol., 28: 277-288.
42. Valencia, I., G. Pinol-Ripoll and D.S. Khurana, H.H. Hardison and S.V. Kothare et al., 2009. Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. Eur. J. Paediatr. Neurol., 13: 141-145.
43. Valentin, A., N. Hindocha, A. Osei-Lah, L. Fisniku and D. McCormick et al., 2007. Idiopathic generalized epilepsy with absences: Syndrome classification. Eprlepsra, 48: 2187-2190. (Pubitemid 350098763)
44. Vrie-Hoekstra, V.D.N.W., T.W.D. Vries, P.D.B.P. Berg, O.F. Brouwer and L.T. de Jong-van den Berg, 2008. Antiepileptic drug utilization in children from 1997-2005 - a study from the Netherlands. Eur. J. Clin. Pharmacol., 64: 1013-1020.